Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Christine Garcia

Thoracic Oncology · NYP Weill Cornell

View

Dr. Timothy Ellis-Caleo

Thoracic Oncology · SU

View

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Saad Usmani

Myeloma · MSK

View

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Hope Rugo

Breast Oncology · City of Hope

View

Dr. Gideon Dosunmu

GI Oncology · Emory Hospital Midtown

View

Dr. Pavlos Msaouel

GU Oncology · MD Anderson Cancer Center

View

Dr. Virginia Borges

Breast Oncology · CU Anschutz Medical Campus

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    MJDr. Mark Jeng
    Leading Voice

    Dr. Mark Jeng

    Hematology & Oncology · Thoracic Oncology
    Memorial Sloan Kettering Cancer Center
    mark
    San Francisco, CA

    Research

    PP01.20: Integrating Clinicopathologic and Genomic Features to Identify Patients at Risk of Earlier Progression to First-Line Osimertinib in EGFR-Mutant NSCLC

    2026

    Via Journal of Thoracic Oncology

    Research

    Prognostic significance of STK11, KEAP1, and NFE2L2- mutations in lung squamous cell carcinoma treated with immunotherapy with or without chemotherapy

    2026

    Via Journal of Clinical Oncology

    Research

    Clinical significance of EGFR amplification in patients with EGFR -mutated metastatic non–small cell lung cancer receiving first-line osimertinib

    2026

    Via Journal of Clinical Oncology

    Research

    Indefinite versus 2 years fixed duration of immune checkpoint inhibition in metastatic non–small cell lung cancer

    2026

    Via Journal of Clinical Oncology

    Research

    Telehealth visits to support extended dosing of pembrolizumab and reduce health care visits: A pragmatic trial

    2026

    Via Journal of Clinical Oncology

    Research

    Cerebrospinal fluid biomarker profiling in patients with non–small cell lung cancer and leptomeningeal disease

    2026

    Via Journal of Clinical Oncology

    Research

    A Phase 2 Basket Trial of Ado-Trastuzumab Emtansine for Patients with HER2 Amplified Cancers: A Non-Randomized Clinical Trial

    2026

    Via Clin Cancer Res

    Research

    Use of a large language model (LLM) for pan-cancer automated detection of anti-cancer therapy toxicities and translational toxicity research

    2025

    Via Journal of Clinical Oncology

    Research

    OGCT-07 ICON-RT: A RANDOMIZED PHASE 2 TRIAL OF CONSOLIDATIVE STEREOTACTIC RADIOSURGERY (SRS) VERSUS CONTINUED OSIMERTINIB IN EGFR-MUTANT NSCLC PATIENTS WITH RESIDUAL BRAIN METASTASES FOLLOWING INITIAL TKI RESPONSE

    2025

    Via Neuro-Oncology Advances

    Research

    Leptomeningeal Metastasis in the Era of CNS-Penetrant Tyrosine Kinase Inhibitors

    2024

    Via PubMed (Journal name not explicitly specified)

    Research

    Lack of disease control remains a major barrier to transplant for relapsed/refractory acute myeloid leukemia: A single-institution experience

    2023

    Via Leukemia Research

    Research

    Beyond single-target ADCs: are bispecific conjugates the next step in EGFR-mutated NSCLC?

    2026

    Via Annals of Oncology

    Research

    Clinicogenomic analysis of EGFR-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation

    2026

    Via Science Translational Medicine

    Research

    Clinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC

    2026

    Via Journal of Thoracic Oncology

    Research

    Cancer type-specific variation in patterns of driver alterations across 50,000 tumors

    2026

    Via Cancer Cell